ASTRAZEN.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 18:00):

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...

Stats
今日成交量	10 944.00
平均成交量	22 237.00
市值	135.48B
EPS	INR0 ( 2024-02-08 )
下一个收益日期	( INR0 ) 2024-05-28
Last Dividend	INR16.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	97.75
ATR14	INR3.40 (0.06%)

音量相关性

長: 0.05 (neutral)

短: -0.92 (very strong negative)

Signal:(40.674) Neutral

AstraZeneca Pharma India 相关性

10 最正相关
SEYAIND.NS	0.834

10 最负相关
CONTROLPR.NS	-0.807

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AstraZeneca Pharma India 相关性 - 货币/商品

-0.31
( neutral )

-0.39
( neutral )

-0.58
( weak negative )

-0.27
( neutral )

0.48
( neutral )

0.52
( weak )

AstraZeneca Pharma India 财务报表

Annual	2022
营收:	INR10.03B
毛利润:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
营收:	INR10.03B
毛利润:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
营收:	INR8.06B
毛利润:	INR4.48B (55.63 %)
EPS:	INR24.60

FY	2021
营收:	INR8.09B
毛利润:	INR4.78B (59.12 %)
EPS:	INR37.30

Financial Reports:

No articles found.

AstraZeneca Pharma India Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR16.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

AstraZeneca Pharma India Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.66 - low (54.78%) | Divividend Growth Potential Score: 2.22 - Decrease likely (55.56%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.70	2003-04-17
Last Dividend	INR16.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR184.10	--
Avg. Dividend % Per Year	0.19%	--
Score	1.47	--
Div. Sustainability Score	4.66
Div.Growth Potential Score	2.22
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-09-25)

INR18.37 Estimate 2.96 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR1.000	0.07%
2020	INR2.00	0.08%
2021	INR2.00	0.04%
2022	INR8.00	0.26%
2023	INR16.00	0.48%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHALBY.NS	Dividend Junior	2023-08-08	Annually	6	0.51%
MANALIPETC.NS	Dividend Junior	2023-09-15	Annually	18	1.50%
GPPL.NS	Dividend Knight	2023-07-26	Semi-Annually	9	2.89%
AXISBANK.NS	Dividend Junior	2023-07-06	Sporadic	26	0.06%
TRU.NS	Dividend Junior	2023-09-18	Annually	3	0.01%
PIXTRANS.NS	Dividend Junior	2023-07-11	Semi-Annually	3	0.43%
JKLAKSHMI.NS	Dividend Junior	2023-08-11	Annually	18	0.50%
DHRUV.NS	Dividend Junior	2023-09-05	Insufficient data to determine frequency	2	0.15%
SOBHA.NS	Dividend Junior	2023-07-28	Annually	18	0.43%
MMP.NS	Dividend Junior	2023-08-18	Annually	4	0.49%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	128.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	9.89	2.00	5.06	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.518	1.000	4.71	4.71	[0.2 - 0.8]
operatingProfitMarginTTM	0.145	1.000	9.10	9.10	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	97.15	1.000	0.288	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
dividendYielPercentageTTM	0.296	1.500	2.61	0	[0 - 0.4]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.86	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0207	1.000	-1.984	0	[0.1 - 0.5]
Total Score				2.22

AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.